Molecular Functional Imaging Lab, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, India; Department of Life Sciences, Homi Bhaba National Institute, Mumbai, India.
Imaging Cell Signaling and Therapeutics Lab, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai, India; Department of Life Sciences, Homi Bhaba National Institute, Mumbai, India.
Biomater Adv. 2022 Dec;143:213153. doi: 10.1016/j.bioadv.2022.213153. Epub 2022 Oct 30.
Photothermal therapy (PTT) has emerged as a fast, precisive, and cost-effective anticancer therapy protocol. Here we applied our previously designed nanomaterial (Tocophotoxil) for prospective PTT application to manage radiation- and chemo-resistant cancers in a preclinical model. A PTT dose vs. efficacy relationship was established for radioresistant breast (ZR-75-1 50Gy, 4T1 20Gy) and chemo-resistant ovarian (A2780LR) cancer cells and tumors in mice models. Compared to the sensitive cases, resistant cells treated with PTT for a shorter duration show higher endurance. However, preclinical tumor xenografts treated with optimal PTT dose show 2-3 fold higher longevity (P ≤ 0.05) of treated mice monitored by non-invasive imaging methods. Elevated ERK and AKT activation in radioresistant or only AKT activation in chemo-resistant cells were contributory to higher cell survival in sub-optimal PTT dose. A comprehensive single-cell Raman map of PTT treated ZR-75-1 cell reveals broad-spectrum macromolecular deformities, including protein damage features. Marked induction of pJNK, unfolded protein response (UPR) pathway, increased reactive oxygen species (ROS), and lipid peroxidation in PTT-treated cells disrupted the intracellular homeostasis. Analyzing cellular ultrastructure, the coexistence of swollen endoplasmic reticulum, and autophagic bodies after PTT indicate possible coordination between UPR and autophagy pathways. Therefore, this comprehensive study provides new evidence on the potential impact of PTT as a standalone therapy for ablation of failed conventional therapy-resistant cancers in vivo, the success of which is intricately linked to the PTT dose optimization. The study, for the first time, also illustrates that under PTT treatment, concerted action of novel molecular switches such as JNK activation and UPR activation plays a vital role in triggering autophagy and cancer cell death.
光热疗法(PTT)已成为一种快速、精准且具有成本效益的抗癌疗法。在这里,我们应用了之前设计的纳米材料(Tocophotoxil),将其应用于临床前模型中的放射和化疗耐药癌症的潜在 PTT 治疗。我们建立了 PTT 剂量与疗效的关系,用于研究放射耐药乳腺癌(ZR-75-1 50Gy,4T1 20Gy)和化疗耐药卵巢癌(A2780LR)细胞和肿瘤。与敏感病例相比,用 PTT 处理较短时间的耐药细胞表现出更高的耐力。然而,用最佳 PTT 剂量处理的临床前肿瘤异种移植物通过非侵入性成像方法监测,可使治疗小鼠的寿命延长 2-3 倍(P≤0.05)。在放射耐药细胞中,ERK 和 AKT 的激活升高,或仅在化疗耐药细胞中 AKT 的激活,有助于在亚最佳 PTT 剂量下提高细胞存活率。对 PTT 处理的 ZR-75-1 细胞进行的全面单细胞 Raman 图谱揭示了广泛的大分子变形,包括蛋白质损伤特征。PTT 处理的细胞中 pJNK 的显著诱导、未折叠蛋白反应(UPR)途径、活性氧(ROS)和脂质过氧化的增加破坏了细胞内的平衡。分析细胞超微结构,PTT 后内质网肿胀和自噬体的共存表明 UPR 和自噬途径之间可能存在协调作用。因此,这项全面的研究为 PTT 作为一种单独的治疗方法在体内消融失败的传统治疗耐药癌症提供了新的证据,其成功与 PTT 剂量优化密切相关。该研究首次还表明,在 PTT 治疗下,JNK 激活和 UPR 激活等新型分子开关的协同作用在触发自噬和癌细胞死亡中起着至关重要的作用。